dendritic cell vaccine therapy + fludeoxyglucose F 18 + laboratory biomarker analysis + NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL + positron emission tomography + FLUDARABINE PHOSPHATE + Cyclophosphamide + ALDESLEUKIN
1 treatment and condition followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| dendritic cell vaccine therapy + fludeoxyglucose F 18 + laboratory biomarker analysis + NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL + positron emission tomography + FLUDARABINE PHOSPHATE + Cyclophosphamide + ALDESLEUKIN for neoplasms | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |